Oxford Nanopore Technolo... Share Discussion Threads

[seball] 01/8/2024 07:43

BioMerieux Mcap another substantial invesotrs has a mcap of 11.8 bln. They will be looking to snap up ONT or merge imo. They bought a substantial amount of ONT in October at twice this price. No smoke without fire. BUY

Also with LAT shares expiring 5th Oct these are going to rerate. Buy now and hold this could easily go up 200% this year.

We all have an opportunity to buy at these ridiculously cheap levels.

[seball] 01/8/2024 07:42

Novo Holdings has made this investment after evaluating the long-term growth opportunities for Oxford Nanopore, in particular those within the Biopharma industry, and after a thorough review of Oxford Nanopore's broad patent portfolio.

[bamboo2] 01/8/2024 07:07

Might we at last have a squeeze?

[bamboo2] 01/8/2024 06:53

The placing may explain the need for this RNS earlier in July.

16 July 2024

...(LSE: ONT) today announces the appointment of Berenberg as joint corporate broker alongside Citigroup Global Markets Limited and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove)...

[bamboo2] 01/8/2024 06:43

Cousin, re 1508
"I'd be a bit miffed if I was bioMérieux at the much lower price Novo have negotiated for their stake."

Presumably bioMerieux could have chosen to obtain some or all of their holding on the open market. Novo may now decide to do this, and anyone still short will have more reason to think about covering.

[bamboo2] 01/8/2024 06:38

Oxford Nanopore attracts investment from Novo Holdings and completes Equity Issue of £80 million

Oxford Nanopore announces the successful completion of the bookbuilding process for the placing of new ordinary shares of £0.0001 each in the capital of the Company ("New Ordinary Shares") announced yesterday (the "Placing"). In light of the strong demand from investors, with the transaction multiple times oversubscribed, the Board has decided to increase the size of the Equity Issue from approximately £75 million to £80 million.

A total of 25,000,000 New Ordinary Shares (the "Placing Shares") have been placed by Citigroup Global Markets Limited ("Citi"), J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) ("J.P. Morgan Cazenove") and Joh. Berenberg, Gossler & Co. KG ("Berenberg" and, together with Citi and J.P. Morgan Cazenove, the "Joint Bookrunners") at a price of 120 pence per Placing Share (the "Placing Price") raising gross proceeds of approximately £30 million.

As a result of the successful placing, the subscription by Novo Holdings A/S ("Novo Holdings") has been reduced from £60 million such that it will subscribe for 41,666,667 New Ordinary Shares (the "Subscription Shares") at the Placing Price, raising gross proceeds of approximately £50 million. Novo Holdings currently intends, subject, inter alia, to availability and price, to add over time to their initial primary investment through further market purchases of up to £10 million.

Therefore, the Placing and Subscription (together, the "Equity Issue") will raise total gross proceeds of approximately £80 million.

Dr. Gordon Sanghera, CEO, Oxford Nanopore said:

"We are delighted to welcome this new, strategic investment from Novo Holdings, alongside continuing support from our existing investors. Over recent years, we have further iterated our technology platform and commercial infrastructure and are poised to gain further traction in broad sectors including scientific research, clinical and applied industrial markets. The investment from Novo Holdings reflects our ambition in the biopharmaceutical sector. Our technology platform is uniquely suited to address the needs of this industry where information-rich, rapid and simplified sequencing are critical to developing and delivering biopharmaceuticals faster and with less complexity. We look forward to their support."

Together, the Placing Shares and Subscription Shares ("New Ordinary Shares") being issued represent approximately 8 per cent. of the issued ordinary share capital of Oxford Nanopore prior to the Equity Issue. The Placing Price of 120 pence represents a discount of approximately 0.7 per cent. to the closing share price of 120.80 pence on 31 July 2024.

As per the new U.K. listing regime, applications have been made for the New Ordinary Shares to be admitted to the "transition" listing segment of the Official List (the "Official List") of the Financial Conduct Authority (the "FCA") and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (the "London Stock Exchange") (together, "Admission"). Settlement of the New Ordinary Shares and Admission are expected to take place on or around 8.00 a.m. on 5 August 2024. The Placing is conditional upon, amongst other things, Admission becoming effective and upon the placing agreement between the Joint Bookrunners and the Company not being terminated in accordance with its terms.

The New Ordinary Shares, when issued, will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares, including, without limitation, the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Following Admission, the total number of Ordinary Shares in issue in Oxford Nanopore will be 940,896,164. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in Oxford Nanopore will be 940,896,164 following Admission, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Nanopore under the FCA's Disclosure Guidance and Transparency Rules.

Citi, J.P. Morgan Cazenove and Berenberg acted as Joint Global Coordinators, Joint Bookrunners and Joint Corporate Brokers in respect of the Placing.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of €149 billion.

www.novoholdings.dk

[seball] 01/8/2024 06:12

200p by October 5th when lat shares expire imo... then bidding war will begin

[seball] 01/8/2024 06:11

This is very positive for the shares. Oversubscribed and Novo will now also be looking to add a further 10m as they only got £50 mil and they wanted £60 mil.
Onwards and upwards

[seball] 01/8/2024 06:09

Dr. Gordon Sanghera, CEO, Oxford Nanopore said:

"Novo Holdings is one of the world's top life sciences investors, and we are delighted to welcome them as a long-term shareholder. The Novo Holdings team brings deep knowledge of the biopharmaceutical market, including biomanufacturing, a key growth area for Oxford Nanopore. Our technology platform is uniquely suited to address the needs of this industry where information-rich, rapid and simplified sequencing are critical to developing and delivering biopharmaceuticals faster and with less complexity. We look forward to their support given our commitment to biopharma as one of our strategic growth vectors."



Dr. Daniel Mahony, Senior Partner, Growth Investments, Novo Holdings said:

"Oxford Nanopore has made impressive ongoing progress to advance its technology platform and gain commercial traction. This investment underscores our belief in Oxford Nanopore's platform and its expanding opportunity in biopharmaceuticals, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new drug therapies. We are confident in Oxford Nanopore's long-term value proposition after extensive due diligence within the biopharma community and analysis of their robust and extensive IP portfolio, and we look forward to supporting the Company going forward."

[cousinit] 31/7/2024 16:31

The cynic in me says the placing gets a chunk of shares into safe hands before the LAT shares expire...

I'd be a bit miffed if I was bioMérieux at the much lower price Novo have negotiated for their stake.

[palisz] 31/7/2024 16:29

Oxford Nanopore attracts investment from Novo Holdings and announces proposed placing of new ordinary shares
The Equity Issue comprises the issue of new ordinary shares of £0.0001 each in the capital of the Company ("New Ordinary Shares"), at an issue price of 120 pence per New Ordinary Share through:
a strategic investment from Novo Holdings A/S ("Novo Holdings"), a world leading life sciences investor, of up to £60 million, pursuant to which Novo Holdings has committed to subscribe for New Ordinary Shares (the "Subscription Shares") at the Placing Price
and..
a placing to institutional investors by the issue of New Ordinary Shares (the "Placing Shares") at the Placing Price (the "Placing").

[chc15] 31/7/2024 14:21

Taken my profits and gone. Good luck all.

[rampmeister] 24/7/2024 14:03

Looks like we are breaking out of 12 month downtrend established since last August. I’m only up around 14% but thinking of increasing up to mid weight holding providing current price level is maintained.

RM

[seball] 24/7/2024 07:08

Buy and hold don't give up your shares cheaply. This is ridiculously undervalued. Good luck all

[seball] 24/7/2024 06:07

No change in guidance and continued confidence to meet 2024 outlook. This will be taken as good news and share price will continue to rise over coming months. This is a sitting duck for a takeover once anti takeover shares expire in October.Good luck all

[bamboo2] 24/7/2024 06:04

24 July 2024

Oxford Nanopore Technologies plc

Half Year Trading Update

· Trading in-line with both revenue and gross margin guidance in the face of challenging end-markets

· Building commercial momentum heading into the second half reinforces confidence; full year 2024 and medium-term guidance reaffirmed

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of molecular sensing technology based on nanopores, today provides a trading update for the six months ended 30 June 2024 ahead of results, which will be published on 3 September 2024.

The Group expects to report Life Sciences Research Tools (LSRT) revenue for the six months ended 30 June 2024 of approximately £84 million (H1 2023: £86.0 million), broadly flat year-on-year at constant currency; marginally down (2%) on a reported basis, including foreign exchange headwinds. Underlying[1] LSRT revenue, grew by 12.4% on a constant currency basis year-on-year. Growth for the first half of 2024 is in-line with expected 2024 phasing.

Underlying growth has been strongest across the PromethION franchise[2], across all product lines. Underlying growth was delivered across each region, and it was strongest across EMEAI and APAC, with commercial momentum building for the second half, supported by new product launches, a number of new and expanded contracts, and a step up in sales team productivity in the second quarter.

Gross margin for the first half is expected to show year-on-year improvement, despite foreign exchange headwinds, and remains on track to meet the Group's full year 2024 guidance.

Outlook

Full year 2024 guidance remains unchanged:

- LSRT revenue growth is expected to be between 6 and 15% on a constant currency basis and underlying revenue growth is expected to be between 20 and 30% on a constant currency basis. The Group continues to expect FY 2024 revenue to be second half weighted, with an approximate 45:55 split.

- Gross margin is expected to be approximately 57%.

All medium-term (FY 2027) guidance is unchanged.



Gordon Sanghera, Chief Executive Officer, commented:

"Our first half performance is in-line with our expectations. We delivered robust underlying revenue growth, despite a challenging macroeconomic backdrop.



"We enter the second half in a strong position; new contract wins coupled with the increased productivity of our sales teams in the second quarter reinforces our confidence in our full year 2024 outlook. In addition, the launch of new products from our regulated pipeline, including GridION Q-Line and ElysION, our sample-to-answer automated sequencing solution, will drive adoption in new clinical and applied markets in the near and medium-term."

[bamboo2] 23/7/2024 09:55

steeple, a test of the breakout level is extremely common.
From a technical pov, we certainly didn't want a pesky little gap left this low down!

[steeplejack] 23/7/2024 09:18

There was 50/- on offer on quote and deal first thing around 121p.'Mark it up,suck them in' seems to be the order of the day and tracking the recent daily price movements has been a tricky exercise.Yet its not really a concern,the fundamentals suggest the stock is oversold and perhaps the trading update tomorrow will consolidate the recent uptrend.The company is very conscious of its poor rating by all accounts.

[bamboo2] 23/7/2024 07:37

Price gapped up this morning from 120.4 eod close yesterday.

Lets get that filled for now.

[bamboo2] 23/7/2024 07:22

RNS NON 23/7/2024
Oxford Nanopore Technologies plc

Oxford Nanopore and Plasmidsaurus announce collaboration and multi-year, multi-million dollar contract expansion

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and Plasmidsaurus, the LA-based company that introduced overnight whole-plasmid sequencing, today announce a new strategic collaboration to advance plasmid sequencing beyond legacy methods, and an expanded multi-year, multi-million dollar global contract.

Plasmidsaurus' whole-plasmid sequencing is used by researchers and industry professionals around the world for a broad spectrum of applications, from basic research to industrial applications, gene therapy, vaccine development, genetic engineering and more. Its sequencing capabilities are based on Oxford Nanopore's real-time, long-read sequencing technology, which has enabled Plasmidsaurus to set new standards for quality and speed, delivering overnight results and richer datasets that unlock more accurate, comprehensive, and reliable insights.

The extension of the existing contract will see the collaboration continue to take share of a fast-growing estimated $1.5B market opportunity in synthetic biology as nanopore-based sequencing continues to displace traditional methods, such as Sanger, for plasmid sequencing. Founded in 2021, Plasmidsaurus has since opened nine labs in three countries and is expanding its global network of 660 dropboxes and labs in key biotech hubs, including new locations in the US, Europe, and Asia. Plasmidsaurus became an Oxford Nanopore customer in 2021.

As strategic collaborators going forward, Oxford Nanopore and Plasmidsaurus also intend to co-develop new technologies, reagents, and applications beyond plasmid sequencing, including microbial and gene therapy use cases, to best meet evolving market needs, providing further market share opportunities.

Gordon Sanghera, CEO of Oxford Nanopore commented:

"By collaborating with Plasmidsaurus, we are advancing the fields of synthetic biology and biotechnology through the unique capabilities of nanopore technology that are not possible with legacy methods. Our joint efforts will drive significant market growth and deliver best-in-class sequencing services to a global audience."

[steeplejack] 22/7/2024 14:44

24 July 2024Half year 2024 trading update3 September 2024Half year results for the six months ended 30 June 2024Optimism ahead of Wednesday's update

[stamford hill] 22/7/2024 14:40

If it closes around this level it will be a confirmed change of trend. Will wait for the inevitable pullback (hopefully)to pick up the kids and buy in..

[apple53] 22/7/2024 10:27

And we're through. Let's see if we can hold. Next minor resistance 122?

[apple53] 22/7/2024 10:15

Well I make that the 6th attempt just now. SOOO tempted to trade it again. Probably would have done if it weren't for stamp.